Skip to main content

BCYC

Stock
Health Care
Biotechnology

Performance overview

BCYC Price
Price Chart

Forward-looking statistics

Beta
0.90
Risk
67.06%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Company info

SectorHealth Care
IndustryBiotechnology
Employees254
Market cap$1.6B

Fundamentals

Enterprise value-$303.3M
Revenue$25.7M
Revenue per employee—
Profit margin0.00%
Debt to equity1.12

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$3.16
Dividend per share—
Revenue per share$0.40
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$3M
Put-call ratio—

Macro factor sensitivity

Growth+18.8
Credit-19.9
Liquidity-9.1
Inflation+19.5
Commodities+6.2
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio-2.09
Price to sales20.00
P/E Ratio-2.09
Enterprise Value to Revenue-11.79
Price to book0.69

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?

Bicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research (October 14, 2024)
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

RBC Capital initiated coverage on Bicycle Therapeutics PLC BCYC, noting an advantage in oncology and beyond.

Benzinga (September 6, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free